Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Most CDK inhibitors have been looked at in both solid and liquid tumors, Flynn says. CDK inhibitors have been looked at in CLL because it is preferable to treat the disease with an agent that has a low toxicity profileâ€‹.
CDK inhibitors have an interesting history in CLL. Alvocidib (flavopiridol) was looked at first, but did not demonstrate much activity. Nevertheless, alvocidib opened the door for other CDK inhibitors in this disease, like dinaciclib.
<<< View more from the 2014 AACR Annual Meeting